WebOct 12, 2024 · OTO-313 utilizes a novel, patent-protected formulation technology to provide several weeks of gacyclidine drug exposure in the inner ear following a single intratympanic injection. In 2024, we... WebOTO-313 is the research name for a drug called gacyclidine, which is currently in stage 2 clinical trials for the treatment of tinnitus. OTO-313/Gacyclidine is in the same class as ketamine (NMDA antagnoist). It essentially blocks the activation a …
Otonomy Reports Corporate and Product Pipeline Update
WebAug 31, 2024 · As used in sections 4513.11 to 4513.115 of the Revised Code: (A) "Boat trailer" means any vehicle designed and used exclusively to transport a boat between a … WebApr 17, 2024 · Official Title: A Randomized, Double-blind, Placebo-controlled Phase 1/2 Study of OTO-313 Given as a Single Intratympanic Injection in Subjects With Subjective Tinnitus. Actual Study Start Date : April 4, 2024. Actual Primary Completion Date : May 29, 2024. Actual Study Completion Date : May 29, 2024. hubei institute for nationalities
Otonomy Reports Results from Phase 2 Clinical Trial of
WebFeb 23, 2024 · Altogether, these multiple clinical data readouts for OTO-313 are expected to support an End-of-Phase 2 meeting with the FDA and inform the design of the Phase 3 clinical program planned to start in the first half of 2024. They're sounding confident indeed! Great to hear that they're closely working with the FDA too while moving things along. WebJul 25, 2024 · OTO-313: top-line results for Phase 2 trial in tinnitus expected in August 2024; patient enrollment completed for safety evaluation of higher and bilateral dosing. … WebMar 25, 2024 · Top-line results expected in mid-2024. SAN DIEGO, March 25, 2024 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initiation of a Phase 2 clinical trial of OTO-313 in patients with unilateral tinnitus. hubei jiangxi hongtai industry co. ltd